医渡科技 20250709 摘要 易都科技净亏损同比收窄 38.9%，OPEX 占收入比例下降 10 个百分点， 经营活动现金流出同比收窄 23.8%，效率和盈利能力显著提升，为未来 盈利增长奠定基础。 易都科技面向医生打造一加 N 加 X 的 CO pilot 产品矩阵，以 AI 中台为 基座，集成 Deep Sick 和医疗垂域大模型等，已在 30 多家头部医疗机 构落地，赋能诊前、诊中、诊后的全流程业务场景。 易都科技在肿瘤疾病领域以肿瘤疾病为核心深度攻克顶级专科机构，如 中肿、北肿和哈肿等，并推出首个由中科院院士滕高军领衔的肝癌诊疗 智能体"小肝人"，已在中肿落地 120 多个新的诊疗场景。 易都科技提供 AI 智能体服务，通过无代码工具链让医生根据需求自行构 建，在重点医院使用人数达全院医护人员的 43%，AI 诊疗助手辅助医生， 两个月内服务患者达 2.6 万次，医院端订单数量同比增长 15%。 易都科技参与新加坡卫生部 MSC home 移动住院护理国家项目，通过 APP Doctor Body 实现出院患者远程监控，将生命体征实时回传并生成 个性化建议，实现离院不离管的新健康管理模式。 Q&A ...

Core Viewpoint - The article discusses the upcoming IPO of a medical AI company backed by Baidu, highlighting the significant interest and potential in the healthcare technology sector, particularly in Hangzhou, Zhejiang [1] Group 1: Company Overview - The medical AI company is based in Hangzhou, Zhejiang, and is preparing for its initial public offering (IPO) [1] - Baidu's investment in the company indicates strong confidence in the growth potential of healthcare AI solutions [1] Group 2: Market Trends - The healthcare technology sector is experiencing rapid growth, driven by advancements in artificial intelligence and increasing demand for innovative medical solutions [1] - The article emphasizes the trend of traditional tech companies, like Baidu, diversifying into healthcare, reflecting a broader industry shift towards integrating technology with medical services [1]

此外，"脑瑞康"大模型能为患者提供便捷、科学的诊疗服务。家属通过手机应用输入症 状和检查结果，AI快速给出病情评估和就诊建议，交互界面简单实用，提高脑出血管理便 捷性和效率。在医生端，急诊科医生利用AI多学科会诊模式，快速整合患者信息，模拟专 家会诊，生成综合治疗方案，缩短多学科协作时间，提升救治效率。 同济医院还将"脑瑞康"作为核心引擎，构建了数智化脑出血血肿抽吸决策系统，专为优 化血肿抽吸手术设计，融合现代科技与医疗理念，实现精准、高效、安全的手术过程。 编辑：赖俊 7月4日，华中科技大学同济医学院附属同济医院联合神州医疗科技股份有限公司，在北 京国家会议中心举行的中国卒中学会第十一届学术年会暨天坛脑血管病会议上，正式发布全 国首个脑出血AI大模型"脑瑞康"。 脑出血在中国发病率高，占脑卒中患者的18.8%～47.6%，发病30天的患者病死率高达 35%～52%。 同济医院神经内科唐洲平教授团队领衔打造的"脑瑞康"脑出血诊疗大模型，由"脑瑞 康"脑出血数据集、"脑瑞康"大模型基座以及BrainHemo多智能体系统构成。"脑瑞康"脑出血 数据集涵盖多模态脑干出血临床真实世界研究数据集与脑出血微创临床真实世界 ...

科技"普惠"并非一蹴而就的浪漫故事，而是由无数"小事"组成的系统工程。 封面来源 ｜ IC photo 在医疗AI的赛场上，又一家大厂开始全力冲刺。 6月26日，进入医疗领域11年后，蚂蚁集团正式发布独立AI健康应用"AQ"。 这是去年9月在支付宝内上线的"AI健康管家"的全新升级版；功能上，不只是问 诊咨询、健康科普 等 常规内容，甚至直接连接起了国内千余家医院、百万医生，以及鱼跃、华为等硬件设备厂商，形 成了覆盖院内院外全周期的健康管理 体系。 换句话说，以后再想找AI问问健康问题，办个异地医保报销，或询问下血糖、血压的控制建议，不必在各个不同的AI助手和APP之间反复"横跳"了，一个 AQ就搞定。 蚂蚁集团副总裁、医疗健康事业部负责人张俊杰表示："AQ将是蚂蚁向AI医疗健康方向发展的新入口。未来，蚂蚁还会联合更多医生、医院、医疗相关企 业，通过AQ为用户提供更普惠的医疗健康服务。" 值得注意的是，这并不是蚂蚁近期在医疗领域官宣的唯一动作。6月30日，蚂蚁集团发布年度ESG报告中，也首次将"普惠医疗健康"升级为集团五大业务板 块之一。 这些变化可能意味着什么？蚂蚁为何押注AQ应用，加速探索AI医疗？ "过 ...

AI+医疗：从蚂蚁 AQ 看产业发展 20260629 摘要 蚂蚁集团推出独立 AI 健康应用"AQ"，源于支付宝平台在医疗支付和数 字化赋能的积累，以及 AI 健康管家小程序超过 7,000 万的用户基础， 旨在抓住健康赛道的巨大潜力。 "AQ"整合了全国超 5,000 家医院、近百万医生及 200 多位三甲专家资 源，以 AI 为主导、专家为辅，提供在线问诊，旨在缓解医疗资源不均和 看病难问题。AI 在诊前可高效整理病历信息，缩短问诊时间，提升就诊 效率。 医疗 AI 商业化主要体现在医生辅助和高效信息助手，尤其在诊前信息整 理和常见病辅助诊断方面。对于专科病和复杂病，AI 提供评估方案辅助 医生决策，但最终诊断仍由医生决定。 医院对数据安全和隐私保护高度敏感，倾向于私有化部署 AI 服务，导致 对集成 GPU 的 DeepSeeker 一体机需求旺盛，订单金额从几十万到几 千万不等，成为产业商业化收入的重要来源。 医疗 AI 领域倾向于通用大模型与垂类大模型混合架构，以适应细分专业 化医疗需求。关键在于结合特定数据特征、专业医生和专家的数据标注 经验，提升 AI 诊疗质量。 Q&A 蚂蚁集团近期推出的独 ...

Group 1 - The Shanghai and Shenzhen Stock Exchanges are seeking public opinion on adjusting the price fluctuation limit for risk warning stocks on the main board to 10%, aligning it with other stocks [1] - The adjustment aims to enhance market consistency and potentially improve trading dynamics for risk warning stocks [1] Group 2 - Guosheng Securities indicates that the "14th Five-Year Plan" is a year for layout, suggesting that market adjustments present opportunities [2] - The macro environment is characterized by economic resilience, policy stability, and high asset volatility, with expectations of a fluctuating A-share market in the second half of the year [2] - The policy approach is divided into two phases: the first focuses on accelerating existing policy implementation, while the second will assess the need for further fiscal stimulus based on economic conditions [2] Group 3 - Guosheng Securities highlights the advantages of stablecoins in payment scenarios, particularly in cross-border payments, and notes the competitive landscape among different stablecoins [3] - The integration of stablecoins with AI agents and the tokenization of U.S. stocks are seen as significant trends that could enhance global financial market liquidity [3] Group 4 - Dongwu Securities reports that the solid-state battery industry is entering a critical mid-test phase, with rapid advancements in the supply chain supported by national policies [6] - The solid-state battery's core components, particularly sulfide electrolytes, are expected to achieve mass production by 2030, with significant progress in manufacturing processes [6] Group 5 - Investment recommendations include focusing on the battery segment with high barriers to entry, suggesting companies like CATL and BYD, as well as equipment and materials sectors [7] - The solid-state battery market is anticipated to see breakthroughs in both equipment and materials, with ongoing developments in production techniques [6][7] Group 6 - The AI healthcare sector in China is experiencing rapid growth, with significant advancements in technology, commercialization, and policy support [8] - Ant Group's launch of the AI health application "AQ" aims to address healthcare needs and connect users with a vast network of medical professionals [8] - Investment opportunities are identified in AI healthcare companies such as Alibaba Health and WeDoctor [9]

医药板块复苏受益于政策支持（商保目录、集采政策边际向好）、资金 回流、AI 技术催化及创新药出海。前四个月国内创新药 BD 事件总金额 达 550 亿美元，首付款超 50 亿美元，显示市场对中国创新药研发能力 的高度认可。 下半年医药投资主线包括创新药、AI 医疗技术、银发经济及 AI 赋能的新 兴医疗技术（如蛋白质预测）。制药公司在 A 股占比较高，值得关注， 而中药板块相对较弱。2025 年上半年创新药企财报亮眼，创新药收入 占比提升。 创新药增长原因包括估值处于历史低位、政策利好预期及 BD 事件频发。 国际巨头对中国创新能力的认可提升了相关公司市值和盈利预期。2025 年上半年重磅 BD 活动频繁，首付款创下纪录，预计下半年仍有大量 BD 预期。 人口结构变化影响消费领域，新生人口下降导致传统消费需求减弱，但 宠物经济快速增长。老年人口比重增加带来银发经济和健康产业的发展 潜力，如人形机器人辅助养老等服务需求提升。 Q&A 今年上半年医药行业的表现如何？有哪些主要因素推动了这一表现？ 今年上半年，医药行业经历了从底部回暖到逐步走强的过程。创新药板块表现 尤为亮眼，生物医药指数跑赢沪深 300 指数，制 ...

今年4月，一则"上海一患者被AI医生误诊丧命,获赔127万"的新闻在网上疯传，引发广泛关注。后被证 实该消息为假。面对舆论发酵，国家卫健委迅速发声，表示已介入调查网传信息源头，并强调"AI仅是 医疗工具，医生仍是责任主体"。官方重申了2021年发布的《人工智能医用软件产品分类界定指导原 则》，明确AI作为医疗器械管理，若因设备缺陷导致误诊，患者可向医院和厂商共同追责；但医生作 为最终决策者，仍需对诊疗结果负主要责任。 2025年被视作"AI元年"，今年来，国内医疗AI领域迎来井喷式爆发。据统计，国内已有上千家医院先后 宣布完成DeepSeek开源模型的本地化部署。年初，全国首个"AI儿科医生"在国家儿童医学中心北京儿童 医院正式上线应用。医疗AI大模型成为各个医院重点布局的热门赛道……AI与医疗的全面融合似乎不 再是"选择题"而是"必答题"。 一面是强劲刮起的产业风潮，一面是争议不断，医生和患者该如何选择？AI医疗究竟是一场"资本游 戏"，还是一次医疗深度改革的"神助攻"？ "半夜发烧，不想跑医院，就在APP上问了'AI医生'，它建议我先吃退烧药观察，第二天症状加重的话再 去医院，后来到医院确诊了流感。"28 ...

Core Viewpoint - The article discusses the strategic advancements and challenges faced by Shanghai United Imaging Healthcare Co., Ltd. (United Imaging) in the field of AI-driven medical technology, emphasizing its recent A-round financing and the broader implications for the medical AI industry [1][3]. Financing Insights - United Imaging successfully completed an A-round financing of 1 billion RMB, marking a significant investment in AI technology despite the current market's conservative sentiment [1][3]. - This financing reflects a long-term strategic commitment from United Imaging and its investors, recognizing AI capabilities as a core competitive advantage [3]. AI Development Strategy - Founded in late 2017, United Imaging has focused on embedding AI into clinical settings, starting with diagnostic tools and expanding to over 100 products across various medical fields [4][7]. - The company has achieved significant regulatory milestones, including 22 NMPA Class II certifications and 12 Class III certifications, along with FDA and CE approvals for several applications [4]. Business Model Challenges - Despite rapid product development, United Imaging reported revenues of 254 million RMB and a loss of 136 million RMB in 2023, highlighting the ongoing struggle to establish a clear commercial model in the medical AI sector [11][12]. - Key challenges include hospitals' reluctance to pay for software, especially in a cost-controlled environment, and the need for comprehensive solutions that address multiple disease types rather than single-function products [12][13]. Technological Innovations - United Imaging is developing a multi-modal AI platform, uAI, which integrates various data types to enhance clinical workflows and improve diagnostic accuracy [14][17]. - The company aims to create a "smart ecosystem" where AI acts as a self-evolving system, enhancing efficiency across all hospital processes [18][20]. Future Outlook - The medical AI industry is shifting from a focus on model parameters to ecosystem strength, with United Imaging positioning itself as a platform company rather than a tool provider [22][23]. - The company faces high costs associated with continuous model iteration and the integration of AI into clinical settings, but its comprehensive approach may provide a sustainable competitive edge in the long term [24][25].

公开资料显示，鹰瞳科技是全球视网膜影像人工智能领域的领导者，自主研发了软硬一体化的视网膜影 像诊断AI解决方案。通过"便携式智能眼底相机"全自动拍摄患者视网膜照片，云端视网膜影像AI算法精 准识别55种眼部疾病与心梗、中风等高发心脑血管疾病，糖尿病，老年痴呆等慢病风险，即时反馈数字 化报告，诊断结果媲美专家级医生。 中金此前发布研报称，鹰瞳科技立足AI眼底影像筛查细分方向，并布局AI软件解决方案+硬件设备的一 体化产品，提供基于眼底影像筛查的检测诊断和健康风险评估服务。国元国际也表示，公司专注于眼底 及近视防控医疗AI多年，产品力强大，在重大疾病早发现早诊断方面发挥了很重大的医疗价值，随着 重点网点及用户数的快速拓展，以及适逢医疗AI产业的重大发展机遇，公司业绩有望快速增长。 消息面上，近日，《体检人群眼健康筛查及健康管理专家共识（2024）》正式发表于《中华健康管理学 杂志》。《共识》针对我国眼健康管理痛点，提出标准化筛查路径及系统化解决方案。值得注意的是， 《共识》还着重强调了人工智能在辅助诊断方面的巨大潜力。AI系统能够自动识别和分类眼底图像中 的病变特征，为医师提供可靠的诊断参考。这一技术不仅有效减轻 ...